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Purpose: To investigate the prevalence and psychopathological features of psychiatric adverse events (PAEs) in patients with
learning disabilities (LD) in therapy with levetiracetam (LEV).
Method: From a population of 517 consecutively patients with epilepsy started on LEV, we identified 118 patients with epilepsy
and LD.
Results: Fifteen patients (12.7%) experienced PAEs during LEV therapy. Two (1.7%) developed an affective disorder, nine
(7.6%) aggressive behaviour, two (1.7%) emotion lability and two (1.7%) other personality changes such as agitation, anger and
hostile behaviour. We observed a significant association with a previous history of status epilepticus and a previous psychiatric
history. We did not find a statistically significant association with epilepsy diagnosis, age at onset or duration of the epilepsy,
EEG or MRI features. The titration schedule of LEV appeared not to be relevant.
Conclusions: LEV therapy was well tolerated in patients with epilepsy and LD and the main problems were related to aggres-
sive behaviour. The titration schedule of LEV was not relevant and a subgroup of patients appeared to be biologically more
vulnerable.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Levetiracetam (LEV) has been recently approved for
the treatment of partial epilepsy and preliminary evi-
dence suggests that it can also be effective in gener-
alised epilepsies1. Controlled clinical trials reported a
good tolerability profile and a low rate and mild sever-
ity of the adverse events2.
Adults with learning disabilities (LD) have a higher
incidence of all types of epilepsy than the general
population and up to a forth of patients with epilepsy
have LD3. Moreover, the presence of psychiatric
comorbidity in patients with epilepsy and LD has
been widely described and might represent an im-
portant variable complicating the management of the
patients4.
The aim of our study was to evaluate the preva-
lence and psychopathological features of psychiatric
adverse events (PAEs) in patients with LD in therapy
with LEV, to assess their relationship to seizure pat-
tern and frequency, titration schedule and prescription
time of LEV and to identify significant predictive and
prognostic factors.
METHODS
LEV was available in UK at the end of 2000. Data
were collected from a population of consecutive
patients with epilepsy taking LEV, prospectively col-
lected from the National Hospital for Neurology and
Neurosurgery (Queen Square and Chalfont Center
sites).
The diagnosis of LD (mental retardation or intellec-
tual disability) was made if patients had an intelligent
quotient (IQ) less than 70.
PAEs were assessed by evaluating patients at each
visit and were defined as a psychiatric manifestation
that occurred during LEV therapy and were not related
to other AEDs changes, physical illness or personal
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events, in patients without a psychiatric disorder when
LEV was started.
PAEs have been classified according to the DSM IV
classification, while other behavioural changes have
been arbitrarily classified as anger/hostile behaviour,
aggressive or agitated behaviour, irritability, anxiety
and emotional lability.
The following items were investigated: age when
LEV was started, gender, epilepsy and seizure diag-
nosis (according to ILAE classification)5, age at onset
and duration of epilepsy, family history of epilepsy
and/or psychiatric disorder, previous psychiatric his-
tory, personal history of febrile convulsions, MRI and
EEG features, seizure frequency before LEV ther-
apy (classified as 1–10, 11–20 or >20 seizure/month),
antiepileptic drug prescribed, starting dose of LEV
(classified as 250, 500 or 1000 mg), titration schedule
(classified as 1000 mg every 2 weeks, slower or faster),
at least 50% seizure reduction after LEV, seizure free-
dom attained.
The χ2 analysis or Fisher’s exact test was used for
categorical data, while ordinal and linear variables
were assessed by non-parametric tests and one-way
ANOVA. Difference and correlation were considered
statistically significant at P < 0.05. Subsequently, a
regression analysis was used to test whether these fac-
tors were related to PAEs. Following the significant
likelihood ratio test for the full model, a backward se-
lection method was used to reduce the number of vari-
ables. A variable was eliminated if its removal statistic
had a probability ≥0.10.
RESULTS
Follow up information were available for 118 patients
with epilepsy and LD. The M/F ratio was 64/54 and
the mean age± SD was 31.1± 9.3 years. There were
21 patients with a diagnosis of cryptogenic partial
epilepsy, seven with idiopathic generalised epilepsy,
18 with others, e.g. Lennox–Gastaut or West Syn-
drome, 12 with symptomatic generalised epilepsy and
57 with symptomatic partial epilepsy. The duration of
the epilepsy± SD was 26.7± 10.3 years.
Fifteen patients (12.7%) experienced PAEs during
LEV therapy. Two (1.7%) developed an affective dis-
order, nine (7.6%) aggressive behaviour, two (1.7%)
emotional lability and two (1.7%) other personality
changes such as agitation, anger and hostile behaviour.
Ten (8.5%) patients discontinued LEV because of
PAEs, three (2.5%) received a dose reduction and two
(1.7%) patients remained on the same dose. The mean
dose of LEV at PAEs onset was 1516± 1006 mg/day
while the time of onset of PAEs was 87.6± 85.2 days
after LEV was started. PAEs occurred 15.7 ± 11.3
days after a change in LEV dose.
Table 1: Demographic data and distribution of variables
associated with PAEs.
Variables LD with LD without
PAEs (15) PAEs (103)
Gender (male/female) 10/5 54/49
Age (mean ± SD, years) 30 ± 7.9 31.2 ± 9.5
Duration of epilepsy
(mean ± SD, years)
26.3 ± 6.5 26.7 ± 10.8
History of status epilepticus 10** 22
Titration schedule (1000 mg
every 2 weeks/faster/slower)
4/2/9 36/6/61
50% seizure reduction 8 31
Seizure freedom attained 3 7
Past psychiatric history 9* 21
* P = 0.009; ** P = 0.001.
Table 2: Regression analysis of variables for PAEs in
patients with LD in therapy with LEV.
Variables Wald OR (95% CI) P-value
Previous psychiatric
history
9.256 5.8 (1.87–18.29) 0.002
Previous history of
status epilepticus
8.432 6.4 (1.83–22.54) 0.004
Psychotropic drug prescription was required in three
(2.5%) patients while only one (0.8%) patient was
admitted to hospital because of PAEs.
We did not find a specific seizure pattern associated
to PAEs onset. Three (2.5%) patients were seizure
free during PAEs, one (0.9%) was seizure free but
behaviour deteriorated after a cluster of seizures, five
(4.2%) experienced no change in seizure frequency,
five (4.2%) had seizure reduction and only one (0.9%)
patient experienced seizure worsening.
Comparing patients with and without PAEs, we
found a significant association with the previous
psychiatric history and a previous history of status
epilepticus (Tables 1 and 2).
DISCUSSION
In clinical practice, it is often difficult to recognize
potential side effects of AEDs. Patients with LD may
be unable to express what they feel, and changes in
mood and behaviour may be all that is apparent.
In our study, the prevalence of PAEs was similar
to that described in previous controlled clinical stud-
ies of LEV involving general population of patients
with epilepsy2 and suggests that patients with LD are
not more prone to develop psychopathology taking
LEV. Moreover, the low percentage of psychotropic
drug prescription and hospitalisation because of the
PAEs, suggests that the prognosis of these episodes
was good.
The identification of previous psychiatric history
and previous history of status epilepticus as risk
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factors, suggests that a subgroup of patients is bio-
logically more vulnerable to PAEs. Status epilepticus
has been widely described as one of the variables
that contribute to epileptogenic processes, the main
hypothesis regarding neuronal loss and synaptic re-
organization mainly in the limbic system6. These
phenomena might explain the biological vulnerability
of a subgroup of patients to develop psychopathology
during LEV therapy.
The association between PAEs and previous psychi-
atric history has been widely described7 suggesting
that some AEDs could drive the underlying constitu-
tional lability of some patients, the direction in which
they are driven being given by the past psychiatric pro-
file. The past psychiatric profile was shown to be an
important predictive factor in this study (OR = 5.8).
In our study, most of the patients who developed
psychopathology had a previous history of aggressive
behaviour. It is interesting to note that aggressive be-
haviour was the primary PAEs while psychosis was
not present. On one hand, psychosis is rather difficult
to diagnose in patients with LD, mainly in relation-
ship to their inabilities to express their feelings and
communicate delusions or describe hallucinations, so
that, aggressiveness could be the only manifestation
of a psychotic episode. Generally, a bizarre behaviour
or some behavioural changes such as suspicious-
ness or social withdrawal may give some clues to
the neuropsychiatrist to introduce an antipsychotic
treatment.
On the other hand, the absence of an association
between psychopathology and seizure pattern is in-
triguing and the rather rare prevalence of psychosis
in patients with LD raise the question of whether the
forced normalisation phenomenon exists in patients
with LD. First of all, patients with LD usually have
more severe form of epilepsy and a complete seizure
control is difficult to achieve. Secondly, most of
these patients have epileptic encephalopathies where
multiple foci may be present, reducing the chances
of sudden seizure suppression and ‘forced’ normal-
isation of the EEG. Therefore, our results, taken
together, may bring further evidence on the role of
biological phenomena in the genesis of some aspects
of psychopathology of epilepsy such as psychosis.
Studies assessing the relationship between behaviour
and antiepileptic drugs with different mechanisms of
action in patients with epilepsy and LD should be
needed.
CONCLUSIONS
LEV was well-tolerated in patients with epilepsy and
LD and the titration schedule of the drug was not rel-
evant to develop PAEs. A subgroup of patients seems
to be biologically more vulnerable to psychopathol-
ogy. Aggressive behaviour represented the main drug
related psychiatric comorbidity.
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